The primary strength of this study lies in its demonstration that ATX may be a robust independent predictor of HCC recurrence in patients treated with curative RFA, surpassing the performance of conventional tumor markers, such as AFP and PIVKA‐2. The gene discussed is AFP; the disease is hepatocellular carcinoma.